The information shown in this section is aimed exclusively at health professionals, as specialised training is required to interpret it correctly.

Musculoskeletal system

Therapeutic application of Endoret® (PRGF®) in orthopaedic surgery and sports medicine has been revealed as one of the most effective treatments for arthrosis, tendon, ligament and muscular injuries, as well as in the recuperation of fractures or surgical interventions.


Outpatient procedures


Autologous fibrin acts as an excellent system of gradual local release of growth factors, largely responsible for the clinical efficacy of the treatment.

Endoret® (PRGF®) technology is specifically indicated for arthrosis. Its application can slow the progress of the disease, reduce pain and inflammation and improve patient mobility and quality of life, with no side effects.

Endoret® (PRGF®) is the only plasma rich in growth factors which has been proven to be effective in two clinical trials at evidence level I.



Endoret® (PRGF®) is indicated as treatment for arthrosis of the hips, knees and hands. The degrees of arthrosis to be treated are: grade I, II or III (according to the Ahlback scale)


  • Delays progression of the arthrosis
  • Reduces inflammation and pain effectively
  • Lessens joint rigidity
  • Improves the patient's function and mobility
  • Improves the patient's quality of life


Osteochondritis of the astragalus

Endoret® (PRGF®) technology is indicated for the treatment of chondral injuries at a surgical level.

In these cases, Endoret® (PRGF®) improves the repair of the cartilage and considerably reduces the signs of post-operative inflammation.



Osteochondritis dissecans
  • Chondral injuries with non-viable fragments
  • Extensive chondral injuries and necrosis
  • Avascular necrosis of the hip


  • Reduces the signs of post-operative inflammation
  • Enables the patient to recover mobility more quickly
  • Reduces post-operative complications
  • Improves cartilage repair

Treatment with Endoret® (PRGF®). Clinical protocols backed by clinical trials performed with Endoret® (PRGF®) technology.

Tendon and ligament pathology

Ultrasound-guided infiltration of ENDORET for tendinopathy

Endoret® (PRGF®) technology is indicated to treat tendinopathy and ligament injuries. Its application as an outpatient procedure reduces the recovery time for this type of wound and may be a alternative to reconstructive surgery.

Endoret® (PRGF®) stimulates the proliferation of the tendon cells and increases the synthesis of key molecules such as VEGF and HGF.



Chronic tendinopathy
  • Acute tendon rupture
  • Chronic tendon rupture in patients with a low functional demand
  • Torn ligaments


  • Reduces healing times
  • Delays reconstructive surgery
  • Absence of fibrosis
  • Regeneration with quality tissue (like the original)

Tendon and ligament pathology

When combining Endoret® (PRGF®) with surgery, the fibroblasts of the tendon itself are more effective when synthesising type I pro-collagen, VEGF and HGF. This fact may be definitive for inducing the proliferation of fibroblasts, promoting angiogenesis and preventing fibrotic tissue.



Partial or complete acute tendon rupture in young patients

Treatment with Endoret® (PRGF®). Clinical protocols backed by clinical trials performed with Endoret® (PRGF®) technology.

Muscle pathology

MRI of the tear in the proximal portion of the rectus femoris muscle, showing acute signs of injury in the axial planes.

Endoret® (PRGF®) technology is suitable for treatment of muscle injuries. Its application as an outpatient procedure reduces the recovery time for this type of injury with an almost zero rate of recurrence.

Endoret® (PRGF®) contains multiple growth factors that stimulate different steps of myogenesis, including proliferation, differentiation, migration and the fusion of muscle cells.



  • Muscle tears


  • Reduces pain and swelling
  • Reduces the healing time
  • Reduces fibrosis
  • Reduces the rate of recurrence

Clinical efficacy in tendinopathy and ligament injuries confirmed by publications using Endoret® (PRGF®) technology

Intended for international use only. Indications for use of products and/or therapies contained herein may not be cleared /approved for use by the following Health international agencies: US Food & Drug Administration, Health Canada or Japanese Health Ministry. To access the specific information of your market, use the country selector located on the top menu of this page.

Are you interested in contacting us?